摘要
Abstract
Objective To analyze the clinical application efficacy of magnesium isoglycyrrhizinate in transcatheter arte-rial chemoembolization (TACE) for the treatment of patients with primary liver cancer. Methods 97 cases of patients with primary liver cancer undergoing TACE in our hospital from January 2011 to December 2013 were collected and randomly divided into observation group (62 cases) and control group (35 cases),the control group were received com-monly used drugs for the treatment of liver,the observation group were received 150 mg isoglycyrrhizinate magnesium+250 ml 5% glucose solution intravenously on the basis of control group.The adverse reactions,liver cell damage indica-tors [aspartate aminotransferase (AST),alanine aminotransferase (ALT) and total bilirubin (TBiL)] and indicators of liver cell synthesis [albumin (Alb),total protein (TP) and cholinesterase (CHE)] between the two groups was compared. Re-sults The incidence of adverse reaction in observation group was lower than that in control group,the difference was sig-nificant (P<0.05).After 2 days of TACE,AST,ALT,TBiL in the two groups was higher than that before surgery (P<0.05);After 5 days of TACE,AST and ALT of observation group had no significant difference compared with before surgery (P>0.05),but that of control group was higher than that before surgery (P<0.05).After 2 and 5 days of TACE,Alb,TP, CHE in the two groups was decreased compared with before surgery (P>0.05),but there was no significant difference be-tween the two groups (P>0.05). Conclusion Magnesium isoglycyrrhizinate applying in TACE for the treatment of prima-ry liver cancer can effectively protect liver function,and reduce the side effects of TACE,should be widely applied in clinic.关键词
原发性肝癌/异甘草酸镁/肝动脉化疗灌注及栓塞Key words
Primary liver cancer/Magnesium isoglycyrrhizinate/Transcatheter arterial chemoembolization分类
医药卫生
